| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |